{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14
  ],
  "modelUsed": "claude-opus-4-5",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary QTc Evaluation Objective",
        "text": "To evaluate whether evobrutinib administered as a single oral dose (as solution) of 45 mg or 225 mg prolongs QT/QTc in comparison to placebo control",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "QTc Assay Sensitivity Objective",
        "text": "To demonstrate QTc assay sensitivity",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety and Tolerability Objective",
        "text": "To assess the safety and tolerability of evobrutinib",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "ECG Parameters Objective",
        "text": "To assess the effect of evobrutinib on other ECG parameters",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Pharmacokinetics Objective",
        "text": "To determine the PK of evobrutinib at 45 mg and 225 mg oral dose (solution) under fasting conditions and moxifloxacin at 400 mg oral dose",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8",
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary QTcF Endpoint",
        "text": "ΔΔQTcF (placebo-corrected change from baseline QTcF) for evobrutinib; with concentration-QTc analysis as primary analysis",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Moxifloxacin QTcF Endpoint",
        "text": "ΔΔQTcF (placebo-corrected change from baseline QTcF) for moxifloxacin",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Treatment-Emergent Adverse Events Endpoint",
        "text": "Nature, occurrence, and severity of TEAEs",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "Safety Laboratory Tests Endpoint",
        "text": "Absolute values and changes in safety laboratory tests",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_5",
        "name": "Vital Signs Endpoint",
        "text": "Vital signs assessed from time of first dose to end of study participation",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_6",
        "name": "Safety ECG Endpoint",
        "text": "Single 12-lead ECGs evaluated by Investigator",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_7",
        "name": "Other ECG Parameters Endpoint",
        "text": "QT, QTcB, QTcI, PR, QRS, RR, HR, cardiologist assessment including T-wave morphology, and U-wave",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_8",
        "name": "Evobrutinib PK Endpoint",
        "text": "AUC0-24, AUC0-∞, Cmax, and tmax for evobrutinib and major metabolite",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_9",
        "name": "Moxifloxacin PK Endpoint",
        "text": "AUC0-24, AUC0-∞, Cmax, and tmax for moxifloxacin",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      }
    ],
    "estimands": [],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 4,
      "exploratoryObjectives": 0,
      "totalEndpoints": 9,
      "totalEstimands": 0
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary QTc Evaluation Objective",
        "text": "To evaluate whether evobrutinib administered as a single oral dose (as solution) of 45 mg or 225 mg prolongs QT/QTc in comparison to placebo control",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Primary Objective"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "QTc Assay Sensitivity Objective",
        "text": "To demonstrate QTc assay sensitivity",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety and Tolerability Objective",
        "text": "To assess the safety and tolerability of evobrutinib",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_3",
          "ep_4",
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "ECG Parameters Objective",
        "text": "To assess the effect of evobrutinib on other ECG parameters",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Pharmacokinetics Objective",
        "text": "To determine the PK of evobrutinib at 45 mg and 225 mg oral dose (solution) under fasting conditions and moxifloxacin at 400 mg oral dose",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/objectiveLevel",
          "decode": "Secondary Objective"
        },
        "endpointIds": [
          "ep_8",
          "ep_9"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary QTcF Endpoint",
        "text": "ΔΔQTcF (placebo-corrected change from baseline QTcF) for evobrutinib; with concentration-QTc analysis as primary analysis",
        "level": {
          "code": "Primary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Primary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_2",
        "name": "Moxifloxacin QTcF Endpoint",
        "text": "ΔΔQTcF (placebo-corrected change from baseline QTcF) for moxifloxacin",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Efficacy",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_3",
        "name": "Treatment-Emergent Adverse Events Endpoint",
        "text": "Nature, occurrence, and severity of TEAEs",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_4",
        "name": "Safety Laboratory Tests Endpoint",
        "text": "Absolute values and changes in safety laboratory tests",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_5",
        "name": "Vital Signs Endpoint",
        "text": "Vital signs assessed from time of first dose to end of study participation",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_6",
        "name": "Safety ECG Endpoint",
        "text": "Single 12-lead ECGs evaluated by Investigator",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_7",
        "name": "Other ECG Parameters Endpoint",
        "text": "QT, QTcB, QTcI, PR, QRS, RR, HR, cardiologist assessment including T-wave morphology, and U-wave",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Safety",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_8",
        "name": "Evobrutinib PK Endpoint",
        "text": "AUC0-24, AUC0-∞, Cmax, and tmax for evobrutinib and major metabolite",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      },
      {
        "id": "ep_9",
        "name": "Moxifloxacin PK Endpoint",
        "text": "AUC0-24, AUC0-∞, Cmax, and tmax for moxifloxacin",
        "level": {
          "code": "Secondary",
          "codeSystem": "http://www.cdisc.org/USDM/endpointLevel",
          "decode": "Secondary Endpoint"
        },
        "purpose": "Pharmacokinetic",
        "instanceType": "Endpoint"
      }
    ],
    "estimands": []
  }
}